SCHEMBL344366

SCHEMBL344366

Nc1ccc(Cl)cc1C(=O)c1ccncn1

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
RECQL P46063 1/20 0.51
P2RX7 Q99572 1/20 0.47
CCR9 P51686 1/20 0.47
GCK P35557 2/20 0.45
FADS1 O60427 1/20 0.43
GRM4 Q14833 1/20 0.43
NOS2 P35228 1/20 0.41
JAK2 O60674 2/20 0.40
RAB9A P51151 2/20 0.40
SMN1; SMN2 Q16637 2/20 0.40
NPC1 O15118 1/20 0.40
ALDH1A1 P00352 1/20 0.40
LMNA P02545 1/20 0.40
HPGD P15428 1/20 0.40
L3MBTL1 Q9Y468 1/20 0.40
KMT2A Q03164 2/20 0.39
MEN1 O00255 1/20 0.39
POLB P06746 1/20 0.39
GFER P55789 1/20 0.39
GPR6 P46095 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL342047 0.82 RECQL (0.58) RECQLCCR9GCKGRM4RAB9A
SCHEMBL31366584 0.82 RECQL (0.58) RECQLCCR9GCKGRM4RAB9A
SCHEMBL343167 0.79 RECQL (0.51) RECQLCCR9GCKRAB9ANPC1
SCHEMBL28060 0.78 RECQL (0.57) RECQLCCR9GCKFADS1RAB9A
SCHEMBL31366630 0.78 RECQL (0.57) RECQLCCR9GCKFADS1RAB9A
SCHEMBL9540049 0.77 RECQL (0.79) RECQLGCKFADS1NOS2RAB9A
SCHEMBL343781 0.76 RECQL (0.58) RECQLCCR9GCKFADS1GRM4
SCHEMBL10248666 0.74 CCR9 (0.50) P2RX7CCR9GRM4RAB9AALDH1A1
SCHEMBL10248589 0.73 RECQL (0.51) RECQLCCR9GCKFADS1NOS2
SCHEMBL28171086 0.73 P2RX7 (0.61) P2RX7GRM4KMT2AMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 52 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10364240-B2 Aryl sulfonamides ChemoCentryx. Inc. (US) 2019-07-30 US disclosed
US-10364240-B2 Aryl sulfonamides ChemoCentryx. Inc. (US) 2019-07-30 US disclosed
US-9890148-B2 Aryl sulfonamides CHEMOCENTRYX, INC. (US) 2018-02-13 US disclosed
US-9890148-B2 Aryl sulfonamides CHEMOCENTRYX, INC. (US) 2018-02-13 US disclosed
US-20170369483-A1 ARYL SULFONAMIDES CHEMOCENTRYX, INC. (US) 2017-12-28 US disclosed
US-20150080351-A1 ARYL SULFONAMIDES CHEMOCENTRYX, INC. 2015-03-19 US disclosed
US-20150080351-A1 ARYL SULFONAMIDES CHEMOCENTRYX, INC. 2015-03-19 US disclosed
US-20150080351-A1 ARYL SULFONAMIDES CHEMOCENTRYX, INC. 2015-03-19 US disclosed
EP-1798223-B2 Aryl sulfonamides CHEMOCENTRYX INC (US) 2014-07-30 EP disclosed
EP-1798223-B2 Aryl sulfonamides CHEMOCENTRYX INC (US) 2014-07-30 EP disclosed
US-7420055-B2 Antagonists of the chemokine receptor 9 (CCR9); inhibit TECK ligand; antiinflammatory agents and immunoregulators; inflammatory bowel disease; (2-phenylsulfonamidophenyl)-pyridinyl-methanones; N-[4-chloro-2(pyridine4-carbonyl)-phenyl]4-morpholin-4-yl-benzenesulfonamide CHEMOCENTRYX, INC. (US) 2008-09-02 US disclosed
EP-1798223-A2 Aryl sulfonamides ChemoCentryx Inc (US) 2007-06-20 EP disclosed
US-20060111351-A1 Aryl sulfonamides CHEMOCENTRYX, INC. 2006-05-25 US disclosed
WO-2005112925-A1 ARYL SULFONAMIDES CHEMOCENTRYX (US) 2005-12-01 WO disclosed
US-6939885-B2 Aryl sulfonamides CHEMOCENTRYX (US) 2005-09-06 US disclosed
EP-1562940-A2 ARYL SULFONAMIDES ChemoCentryx Inc (US) 2005-08-17 EP disclosed
US-20050165067-A1 Aryl sulfonamides CHEMOCENTRYX 2005-07-28 US disclosed
US-20050137193-A1 Aryl sulfonamides CHEMOCENTREYX 2005-06-23 US disclosed
US-20040171654-A1 Aryl sulfonamides CHEMOCENTRYX, INC. 2004-09-02 US disclosed
WO-2004046092-A2 ARYL SULFONAMIDES CHEMOCENTRYX (US) 2004-06-03 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050137193-A1 Aryl sulfonamides CCR9, CCR1, CCR2 RECQL 4746/4885P2RX7 179/4885CCR9 1/4885
US-10364240-B2 Aryl sulfonamides CCR9, CCR1, CCR2 RECQL 4746/4885P2RX7 179/4885CCR9 1/4885
US-20060111351-A1 Aryl sulfonamides CCR9, CCR1, CCR2 RECQL 4746/4885P2RX7 179/4885CCR9 1/4885
US-20170369483-A1 ARYL SULFONAMIDES CCR9, CCR1, CCR2 RECQL 4746/4885P2RX7 179/4885CCR9 1/4885
US-20150080351-A1 ARYL SULFONAMIDES CCR9, CCR1, CCR2 RECQL 4746/4885P2RX7 179/4885CCR9 1/4885
US-20040171654-A1 Aryl sulfonamides CCR9, CCR1, CCR2 RECQL 4746/4885P2RX7 179/4885CCR9 1/4885
US-20050165067-A1 Aryl sulfonamides CCR9, CCR1, CCR2 RECQL 4746/4885P2RX7 179/4885CCR9 1/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.